Onyx Pharmaceuticals announced interim results from an ongoing Phase 2 study of carfilzomib for the treatment of multiple myeloma. This open-label, single agent ongoing study, known as the 004 study, is being conducted in collaboration with the Multiple Myeloma Research Consortium, and enrolled approximately 150 patients with relapsed and/or refractory multiple myeloma who have received 1-3 prior treatments. Patients include two populations: Velcade (bortezomib)-naive patients with relapsed and/or refractory multiple myeloma and Velcade-treated patients with relapsed and/or refractory multiple myeloma.
Carfilzomib demonstrated encouraging overall response rates (ORR), tolerability and durable disease control when administered as a single-agent in patients with relapsed and/or refractory multiple myeloma. In 53 evaluable Velcade-naïve patients, carfilzomib achieved an overall response rate of 55 percent at 27mg/m2. Patients in this group also achieved time-to-progression (TTP) of 11.5 months and duration of response (DOR) of 11.5 months. Forty percent of patients were refractory to their most recent therapy prior to entering the trial.
Carfilzomib is a selective, next-generation proteasome inhibitor that is being investigated in a broad clinical trial program in multiple myeloma.
For more information call (510) 597-6500 or visit www.onyx-pharm.com.